ADC THERAPEUTICS SA (ADCT) Stock Income Statement
USA - New York Stock Exchange - NYSE:ADCT - CH0499880968 - Common Stock
4.01 USD
+0.48 (+13.6%)
3.83 USD
-0.18 (-4.49%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 75.21M | 70.84M | 69.56M | 209.90M | 33.90M | |||
| Cost Of Goods | 5.47M | 5.95M | 2.53M | 2.10M | 1.40M | |||
| Gross Profit | 69.74M | 64.89M | 67.03M | 207.80M | 32.50M | |||
| Operating Expenses | 192.29M | 195.54M | 233.01M | 328.70M | 302.30M | |||
| Research and Development | 112.92M | 109.63M | 127.13M | 185.90M | 164.00M | |||
| Selling, General, and Administrative Expenses | 79.36M | 85.91M | 105.89M | 140.60M | 135.80M | |||
| Operating Income | -122.55M | -130.65M | -165.99M | -120.90M | -269.80M | |||
| Interest Income/Expense | -42.05M | -37.72M | -35.34M | 8.00M | 10.00M | |||
| Other Income/Expense | 12.22M | 12.24M | 5.91M | 400.00K | 200.00K | |||
| Non Recurring Items | N/A | N/A | 0.00 | -42.10M | 8.10M | |||
| Income Before Taxes | -165.84M | -156.14M | -195.42M | -154.70M | -251.50M | |||
| Income Tax | 1.10M | 166.00K | 39.11M | 1.10M | -21.50M | |||
| Net Income | -166.94M | -157.85M | -240.05M | -155.80M | -230.00M | |||
| EBITDA | -122.99M | -129.32M | -164.80M | -118.57M | -267.17M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.51 | -1.62 | -2.94 | -1.99 | -3.00 | |||
| Non GAAP EPS | -1.33 | -1.65 | -2.93 | -2.01 | -2.80 | |||
| Statistics | ||||||||
| Gross Profit Margin | 92.73% | 91.60% | 96.36% | 99.00% | 95.87% | |||
| Profit Margin | -221.97% | -222.83% | -345.11% | -74.23% | -678.47% | |||
| Operating Profit Margin | -162.94% | -184.44% | -238.63% | -57.60% | -795.87% | |||
All data in USD